Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2009 Feb;6(1):77-8.
doi: 10.2174/156720509787313871.

The perils of Alzheimer's drug development

Affiliations
Editorial

The perils of Alzheimer's drug development

Lon S Schneider et al. Curr Alzheimer Res. 2009 Feb.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. Altstiel LD. Barriers to Alzheimer's disease drug discovery and development in the biotechnology industry. Alzheimer's Disease and Associated Disorders. 2002;(Supp 1):S29–S32. - PubMed
    1. Becker RE, Greig NH. Alzheimer's Disease Drug Development in 2008 and beyond: Problems and Opportunities. Current Alzheimer Research. 2008;5(4):346–57. - PMC - PubMed
    1. Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology. 1998;50(3):669–77. - PubMed
    1. Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, Hagman G, Lärksäter M, Winblad B, Zetterberg H, Blennow K, Långström B, Nordberg A. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol. 2008 May;63(5):621–31. - PubMed
    1. Poirier J, Delisle M, Quirion R, Aubert I, Farlow M, Lahiri DK, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, Gauthier S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 1995;92:12260–12264. - PMC - PubMed

MeSH terms